Today, Suzhou Ribo Life Science Co., Ltd. (hereinafter referred as Ribo), a leading innovative oligonucleotide therapeutics company in China, announced that its independently developed siRNA drug RBD2080, for the treatment of autoimmune diseases, has been approved by the Therapeutic Products Administration (TGA) of Australia. Phase I clinical trial in Australia will be launched soon.

The Phase I clinical trial is a randomized, double-blind, and placebo-controlled study, to be conducted in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of subcutaneously administered RBD2080. 

RBD2080 is the 6^th innovative siRNA drugs developed by Ribo based on its proprietary RIBO-GalSTAR^TM liver-targeting technology platform, which precisely targets specific genes associated with autoimmune diseases, effectively regulating gene expression to fundamentally intervene the disease process. Compared to traditional therapies, RBD2080 shows advantages in target precision and sustained efficacy, potentially providing patients with better treatment options.